<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016887</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068609</org_study_id>
    <secondary_id>GER-LGLSG-INTERGROUP-20995</secondary_id>
    <secondary_id>EORTC-20995</secondary_id>
    <secondary_id>GELA-INTERGROUP-20995</secondary_id>
    <secondary_id>GISL-INTERGROUP-20995</secondary_id>
    <nct_id>NCT00016887</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma</brief_title>
  <official_title>Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Low Grade Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses&#xD;
      high-energy x-rays to kill cancer cells. Peripheral stem cell transplant may allow the doctor&#xD;
      to give higher doses of chemotherapy drugs and kill more cancer cells. Interferon alfa may&#xD;
      interfere with the growth of cancer cells. It is not yet known whether giving more than one&#xD;
      drug (combination chemotherapy) with radiation therapy and peripheral stem cell transplant is&#xD;
      more effective than chemotherapy followed by interferon alfa in treating mantle cell&#xD;
      lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial compares how well chemotherapy followed by radiation&#xD;
      therapy, chemotherapy, and peripheral stem cell transplant works compared to chemotherapy&#xD;
      plus interferon alfa in treating patients who have stage III or stage IV mantle cell&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the disease-free survival of patients with previously untreated advanced mantle&#xD;
           cell lymphoma treated with intensified chemotherapy followed by myeloablative&#xD;
           radiochemotherapy and peripheral blood stem cell transplantation (PBSCT) vs standard&#xD;
           therapy and interferon alfa maintenance.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with early vs late myeloablative&#xD;
           radiochemotherapy and PBSCT.&#xD;
&#xD;
        -  Compare disease-free survival and overall survival of patients treated with this regimen&#xD;
           vs historic controls of similar cases.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk&#xD;
      factors (ECOG performance status greater than 1, LDH serum level above normal, and/or&#xD;
      extranodal lymphoma involvement) and participating center. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Induction: All patients receive 4 courses of cytoreductive chemotherapy comprising an&#xD;
           anthracycline-containing combination. Patients not achieving complete remission after 4&#xD;
           courses receive 2 additional courses of induction chemotherapy. Patients without at&#xD;
           least a partial response after 6 courses discontinue treatment; those with at least a&#xD;
           partial response proceed to arm I or II.&#xD;
&#xD;
      Arm I&#xD;
&#xD;
        -  Consolidation: Patients achieving complete or partial remission after 4-6 courses of&#xD;
           induction therapy begin intensified chemotherapy within 6 weeks. Patients receive oral&#xD;
           dexamethasone daily on days 1-10, carmustine IV on day 2, melphalan IV on day 3,&#xD;
           etoposide IV daily and cytarabine IV twice a day on days 4-7. Patients also receive&#xD;
           filgrastim (G-CSF) beginning on day 11 and continuing until peripheral blood stem cells&#xD;
           (PBSC) are harvested.&#xD;
&#xD;
        -  Within 4-6 weeks after PBSC harvest, patients undergo myeloablative radiochemotherapy&#xD;
           comprising radiotherapy on days -6 to -4 and cyclophosphamide IV on days -3 to -2.&#xD;
           Patients then undergo PBSC transplantation on day 0.&#xD;
&#xD;
      Arm II&#xD;
&#xD;
        -  Consolidation: Patients receive 2 additional courses of induction chemotherapy as&#xD;
           consolidation (for a total of 8 chemotherapy courses).&#xD;
&#xD;
        -  Maintenance: Within 4 weeks after arm II consolidation, patients receive interferon alfa&#xD;
           subcutaneously (SC) 3 days a week in the absence of unacceptable toxicity or disease&#xD;
           progression or relapse. Patients who experience first relapse or progression during&#xD;
           maintenance therapy may receive intensified chemotherapy as in arm I.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 210 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2000</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage III or IV mantle cell lymphoma&#xD;
&#xD;
               -  Previously untreated&#xD;
&#xD;
          -  Not qualified for primary potentially curative radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 65 years&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No impairment of liver function (unless due to lymphoma)&#xD;
&#xD;
          -  Transaminases no greater than 3 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No renal insufficiency&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No manifest heart failure or coronary heart disease&#xD;
&#xD;
          -  No severe uncontrolled hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No chronic lung disease with hypoxemia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe uncontrolled diabetes mellitus&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior interferon&#xD;
&#xD;
          -  No prior organ, bone marrow, or peripheral blood stem cell transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior cytostatic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Hiddemann, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universitaet Muenchen - Grosshadern Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. C. Kluin-Nelemans, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Levis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Civile Alessandria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achiel Van Hoof, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AZ Sint-Jan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Alessandria</name>
      <address>
        <city>Alessandria</city>
        <zip>I-15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2003</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

